key: cord-0026760-oia99dpm
authors: Fall, Amary; Kenmoe, Sebastien; Ebogo-Belobo, Jean Thierry; Mbaga, Donatien Serge; Bowo-Ngandji, Arnol; Foe-Essomba, Joseph Rodrigue; Tchatchouang, Serges; Amougou Atsama, Marie; Yéngué, Jacqueline Félicité; Kenfack-Momo, Raoul; Feudjio, Alfloditte Flore; Nka, Alex Durand; Mbongue Mikangue, Chris Andre; Taya-Fokou, Jean Bosco; Magoudjou-Pekam, Jeannette Nina; Noura, Efietngab Atembeh; Zemnou-Tepap, Cromwel; Meta-Djomsi, Dowbiss; Maïdadi-Foudi, Martin; Kame-Ngasse, Ginette Irma; Nyebe, Inès; Djukouo, Larissa Gertrude; Kengne Gounmadje, Landry; Tchami Ngongang, Dimitri; Oyono, Martin Gael; Demeni Emoh, Cynthia Paola; Tazokong, Hervé Raoul; Mahamat, Gadji; Kengne-Ndé, Cyprien; Sadeuh-Mba, Serge Alain; Dia, Ndongo; La Rosa, Giuseppina; Ndip, Lucy; Njouom, Richard
title: Global prevalence and case fatality rate of Enterovirus D68 infections, a systematic review and meta-analysis
date: 2022-02-08
journal: PLoS Negl Trop Dis
DOI: 10.1371/journal.pntd.0010073
sha: fc68f27520aced3eb16bf018773deb66f4a5c5f2
doc_id: 26760
cord_uid: oia99dpm

A substantial amount of epidemiological data has been reported on Enterovirus D68 (EV-D68) infections after the 2014 outbreak. Our goal was to map the case fatality rate (CFR) and prevalence of current and past EV-D68 infections. We conducted a systematic review (PROSPERO, CRD42021229255) with published articles on EV-68 infections in PubMed, Embase, Web of Science and Global Index Medicus up to January 2021. We determined prevalences using a model random effect. Of the 4,329 articles retrieved from the databases, 89 studies that met the inclusion criteria were from 39 different countries with apparently healthy individuals and patients with acute respiratory infections, acute flaccid myelitis and asthma-related diseases. The CFR estimate revealed occasional deaths (7/1353) related to EV-D68 infections in patients with severe acute respiratory infections. Analyses showed that the combined prevalence of current and past EV-D68 infections was 4% (95% CI = 3.1–5.0) and 66.3% (95% CI = 40.0–88.2), respectively. The highest prevalences were in hospital outbreaks, developed countries, children under 5, after 2014, and in patients with acute flaccid myelitis and asthma-related diseases. The present study shows sporadic deaths linked to severe respiratory EV-D68 infections. The study also highlights a low prevalence of current EV-D68 infections as opposed to the existence of EV-D68 antibodies in almost all participants of the included studies. These findings therefore highlight the need to implement and/or strengthen continuous surveillance of EV-D68 infections in hospitals and in the community for the anticipation of the response to future epidemics.

Introduction Enteroviruses (EVs) are a major public health concern worldwide. Although the majority of EV infections are subclinical, they can be associated with a broad spectrum of clinical illnesses mainly in children, including acute respiratory illness, meningitis, encephalitis, myocarditis, pericarditis, conjunctivitis, gastrointestinal diseases, hand-foot-and-mouth disease (HFMD), inflammatory muscle diseases, and rarely, its can lead to neurological complications in severe cases [1] [2] [3] . Enteroviruses are members of the genus Enterovirus (Picornaviridae family). They are non-enveloped, positive-sense single strand RNA viruses with of approximately 7400-7500 nucleotides in length. More than 100 Enterovirus genotypes are currently classified based on their molecular and antigenic properties into seven types associated with human disease (Enterovirus A-D and Rhinovirus A-C) [3, 4] . While Human rhinoviruses tropism is restricted to the respiratory tract, the vast majority of Human enteroviruses infect the gastrointestinal tract, the central nervous system, respiratory tract and other organs such as heart and cause a significant morbidity and mortality worldwide.

First isolated in California, in 1962 [5] , enterovirus D68 (EV-D68) which belongs to the species enterovirus D, circulated at low levels around the world all over the year and infections had been identified sporadically until 2014 [6] [7] [8] and only 699 persons were confirmed infected worldwide before 2014 [7] . In August 2014, virus has emerged and captured public attention when a widespread outbreak of neurological impairment (mostly acute flaccid myelitis (AFM)) and severe respiratory illness has firstly been reported across United States and Canada and affecting more than 2000 persons worldwide, mainly children [5, 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . These severe illness requiring hospitalization and admissions to intensive-care units were potentially fatal particularly in children [7, 16, [18] [19] [20] . This unpredictable outbreak of enterovirus D68 associated to severe respiratory illness and AFM in 2014, led to implementation of enhanced laboratory-based surveillance for enterovirus in many countries.

Following the 2014 outbreak, other waves of EV-D68 infections were observed in 2016 and 2018 with reports of outbreaks in several parts of the world, including Europe [10, [21] [22] [23] [24] [25] [26] , USA [15, 27, 28] , South America [29, 30] , Asia [31, 32] and West Africa [33, 34] . These EV-D68 outbreaks also coincided with waves of AFM. Thus, AFM mainly associated with EV-D68 is now recognized as a global disease, with hundreds of cases reported across Europe [ Given that there are no vaccines approved to protect against EV-D68 infections and given its ability to cause a potential uncontrollable epidemic of severe respiratory illness and potential neurological complications such as AFM, it is important to understand its full epidemiology spectrum, in order to elucidate the patterns and outbreak dynamics of such infections and predict its long-term disease burden and impact on public health. In this review, we seek to systematically review the available literature and assess EV-D68 infections prevalence and case fatality rate in humans.

The Checklist of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) was used in the development and reporting of this review [41] (S1 Table) . The PROSPERO international prospective registry was used for the registration of the protocol (ID: CRD42021229255).

Extensive searches were performed by an investigator in the PubMed, Embase, Web of Science and Global Index Medicus databases from inception to January 05, 2021. To enhance the sensitivity of the search strategy, we used only terms covering the field of EV-D68 infections (S2 Table) . The search strategy was initially applied to PubMed and then adapted to other databases. Other potentially eligible studies were searched from the list of references of included studies.

Titles and abstracts were independently reviewed in Rayyan review tool by two investigators to rule out those who did not meet the inclusion criteria. Studies that reported data in English and/or French on the case fatality rate (CFR) and/or prevalence of current or past EV-D68 infections were included. No restrictions on study design, type of EV-D68 detection method, type of specimen for testing for EV-D68, geographic regions or population category were applied. Studies with selection bias (selection of samples with preliminary Rhinovirus (RV) and/or EV results known for EV-D68 typing), with full texts and/or abstracts not found, duplicates, and with sample size <10 were excluded. Studies in which all generic RT-PCR positives for EV/RV were not typed for EV-D68 were excluded for inappropriate prevalence.

Study eligibility and data retrieval was performed in duplicate from full text articles using Google form. Disagreements were resolved by discussion and consensus among independent investigators. Pre-designed and pre-tested google forms were used to collect the following data: first author name, year of publication, study design, sampling method, number of sites,  time of sample collection, country, study period, age group, population studied, EV-D68 diagnostic method, sample types, number tested for EV-D68, number with EV-D68, number of  deaths among EV-D68 positive, and data from the assessment of risk of bias according to Hoy  et al (S3 Table) [42]. We collected only the first EV-D68 specific screening technique and did not consider the confirmatory screening methods such as sequencing. In studies reporting the EV-D68 prevalence of several different sample types or detection methods for the same participants, we selected the highest prevalence. A single study could contribute to multiple points of prevalence specific to country, population category, sample type and detection technique.

We categorized the countries according to the United Nations Statistics Division (UNSD), World Health Organization (WHO) and income level [43] [44] [45] . The age range was grouped into <5 years, <18 years, and all ages. Population categories included presumably healthy individuals, patients with acute respiratory infections (ARI), acute flaccid myelitis (AFM), and asthma-related illnesses. Patients with respiratory symptoms were considered to be ARI. Patients with respiratory symptoms accompanied by hospitalization or lower respiratory tract infections were considered as severe acute respiratory infections (SARI). Infections were aggregated into current (detection of live virus, RNA and/or viral antigen) and past (detection of antibodies). We presented the individual data of the included studies in a database. We aggregated these individual data with the qualitative variables in number and percentage and the continuous variables in range. Data analyses were carried out using R software version 4.0. 3 [46,47] . The forest plot, the proportions grouped with the 95% confidence interval were obtained by a random-effect meta-analysis [48, 49] . Estimates were obtained following a Freeman-Tukey double arcsine transformation. Cochran's Q test and the I2 statistic were used to assess the possibility of heterogeneity between studies, with the values of p <0.05 and I2> 50% indicating the presence of heterogeneity [48, 50] . The funnel plot and Egger's test were used to assess publication bias, with the skewness of the funnel diagram and the p-value <0.05 indicating the presence of publication bias [51] . The stability of the meta-analyses was assessed by sensitivity analyses including only cross-sectional studies and studies with a low risk of publication bias. Subgroup analyses were conducted according to study design, sampling, timing of sample collection, country, WHO region, UNSD region, country income level, period of study (before and after 2014), age group, category of study population, EV-D68 diagnostic method, and sample type. Subgroup analyses were only conducted when at least 3 studies that fell into at least two different categories applied.

The article selection process is shown in Fig 1. The database search returned 4329 articles including 992 duplicates. A total of 89 articles were included in this meta-analysis after exclusions by title and abstract and full-text eligibility review (S4 Table) [11, [16] [17] [18] 20, 25, 30, [32] [33] [34] 37, . These 89 articles were published between 2011 and 2020 in 39 countries in the 6 WHO regions and mainly in high-income countries (USA, China and Japan) (S5 and S6 Tables). Participants were recruited between 1994 and 2019, but most of the participants were after 2014, when EV-D68 infections emerged in the USA. Most of the studies were cross-sectional and prospective with non-probabilistic recruitment. The recruited participants consisted of presumed healthy individuals and patients with acute respiratory infections, acute flaccid myelitis and asthma-related illnesses. The predominant technique used was RT-PCR to search for EV-D68 RNA in nasopharyngeal samples. About half of the studies had a low risk of bias and no study had a high risk of bias (S7 Table) .

The study with reported death due to EV-D68 infections were conducted in 5 countries: Canada, Japan, Panama, United Kingdom and USA (Fig 2) . Seven deaths in patients with ARI were reported among 1353 participants in two included studies conducted in the United Kingdom and USA [20,58]. The CFR due to EV-D68 infections ranged from 0 to 4.4% in the 10 included studies with a combined random effect rate of 0.0% (95% CI: 0.0-0.1) (Fig 3) [18, 20, 53, 58, 59, 65, 102, 112, 113, 127] . No statistical heterogeneity was observed in the overall estimate of the CFR (I2 = 27.5% [0.0%; 65.2%]).

Studies reporting EV-D68 current infections were conducted in 41 countries across 5 WHO regions: America, Europe, West Pacific, Africa, and Southeast Asia (Fig 2) . A total of 4,440 EV-D68 infections were reported among 204,351 participants with acute respiratory infections, acute flaccid myelitis, asthma-related illnesses, and presumed healthy individuals. EV-D68 current infection prevalences ranged from 0 to 74.3% in the included studies with a combined random effect rate of 4.0% (95% CI: 3.1-5.0) (Fig 4) . Substantial statistical heterogeneity was observed in the overall estimate of the prevalence of EV-D68 current infections (I2 = 99.0% [98.9%; 99.1%]).

Studies reporting EV-D68 past infections were conducted in 4 countries China (four estimates), USA (one estimate), Japan (one estimate) and the Netherlands (one estimate) (Fig 2) . A total of 2390 EV-D68 past infections were reported among 3004 participants with acute flaccid myelitis and presumed healthy individuals in 7 included studies [37, 60, 63, 69, 76, 79, 115] . EV-D68 past infections prevalences ranged from 2.0 to 100.0% in included studies with a combined random effect rate of 66.3% (95% CI: 40.0-88.2) (Fig 5) . Substantial statistical heterogeneity was observed in the overall estimate of the prevalence of EV-D68 past infections (I 2 = 99.5% [99.3%; 99.6%]). 

Egger's test indicates that no publication bias was observed for the estimates of CFR and prevalence of EV-D68 past infections (Table 1) . Egger's test indicates publication bias in estimating 

Relationships between EV-D68 CFR and prevalence (current and past infections) according to study design, sampling approach, timing of sample collection, country, WHO region, UNSD region, country income level, study period, age group, category of study population, diagnostic method, and sample type were established with subgroup analyses (S8 Table) . The CFR was not heterogeneous and none of these factors significantly affected the reported estimates. The prevalence of EV-D68 current infections were significantly higher in hospital outbreak, cohorts, study with non-probabilistic recruitments, prospective studies, countries in the Americas WHO region (USA, Argentina, Mexico, and Canada), high income countries, studies with recruitments made after August 2014, studies in <5 years old, studies recruiting patients with asthma-related diseases and AFM and studies that detected EV-D68 in nasopharyngeal samples by real-time RT-PCR. The prevalence of EV-D68 past infections were significantly higher in studies with non-probabilistic recruitments, in the USA, in high-income countries and in subjects of all ages.

This systematic review provides a summary of the prevalence of EV-D68 past and current infections and its case fatality rate in humans obtained by the exploitation of published articles between 1962 and 2020 in 41 countries across 5 WHO regions: America, Europe, West Pacific, Africa, and Southeast Asia. This review reveals occasional deaths from patients with acute respiratory EV-D68 infections. The combined prevalence of current EV-D68 infections in apparently healthy individuals and patients with ARI, AFM and asthma-related illness was 4%. Current EV-D68 infections were higher in hospital outbreaks, high-income countries in the Americas, in children <5 years, after 2014, and in patients with AFM and asthma-related illnesses. Almost all of the individuals had scars from EV-D68 past infections with a combined prevalence of 66.3%. EV-D68 past infections were present in subjects of all ages and higher in high incomes countries. Although, there is no approved antiviral for EV-D68 infections, this review shows a low case fatality rate with seven deaths in patients with ARI reported among 1353 participants. This low number of deaths can be explained by early management with supportive treatment with careful monitoring focused on potential vital emerging complications. In addition, EV-D68 infections are mainly reported in high-income countries, which may result a better care. In 2018, 96% of identified AFM cases in the USA were admitted to hospital, and 58% to an intensive-care unit [130] . Nonetheless, Enterovirus D68 treatment option is limited to supportive care for mild and severe cases. Sufficient evidence of efficacy of corticosteroids, immunoglobulins or plasma exchange has not been found although these immunomodulatory treatments have often administered during the acute management of this pathology [113] . Fluoxetine was found to have in vitro activity against EV-D68 infections. A recent study on the use of fluoxetine in patients with AFM found that fluoxetine was well tolerated and safe. In addition, immune suppressive therapies have also been used by some centers to target the inflammatory response to infection [131] . It should be noted that recently much progress has been made in the development of the EV-D68 antivirals by targeting various viral proteins and host factors essential for viral replication [132] . However, this intervention was not associated with improved neurologic outcomes [133] .

Overall EV-D68 current infection prevalence around 4.0% was estimated in this study with a range of prevalence of 0.0 and 74.29%. The wide range of prevalence found can be explained by the large variation of the prevalence of EV-D68 infections observed according to the study period, the epidemic context, the geographical location, the target population, as well as the various detection assays. High infection rate in North America may be explained by the fact that outbreaks occurred there before spreading in other geographies. The high prevalence of EV-D68 (current and past infection) observed in developed countries could also be attributed to the establishment of an effective surveillance system and the numerous studies that are carried out. In Europe, increasing awareness of and testing for enterovirus D68 led to 31 enterovirus D68-associated AFM cases reported in 2016, an increase of greater than 10 times compared with 2014 [134] . In contrast, in developing countries such as African countries, the low prevalence of EV-D68 infections can be explained by the unawareness of the virus and the resulting lack of studies carried out. Thus, there may be a silent circulation of the virus as witnessed by retrospective studies carried out in West Africa in 2019 [33, 135, 136] and 2020 [34] which showed circulation of the virus during the epidemics of 2014 and 2016.

In this review the majority of EV-D68 current infections were recorded after the 2014 epidemic. Indeed, minor outbreaks of enterovirus D68 had also been described, with 699 cases confirmed in Europe, Africa, America and Asia from 1970 to 2013 with disease manifestations mainly ranging from mild respiratory symptoms to severe ARI requiring intensive care [7] . The high numbers of EV-D68 infections reported after 2014 in the review can therefore be explain by the multiple outbreaks observed from 2014. Indeed, only during the 2014 EV-D68 infections outbreak, 2287 cases recorded in 20 countries which are mainly located in North America and Europe, but also in Southeast Asia and Chile [7] . Following the 2014 outbreak, an upsurge of EV-D68 infections was also occurred in 2016 and 2018 in almost geographic location [10, 15, 22, 24, 28, [32] [33] [34] 137] . Regarding the study period, since 2014, previously published data on the seasonality of EV-D68 infections have suggested circulation with a biennial epidemic cycle of EV-D68 infections in Europe and North America [70, 138, 139] . Moreover, the periodic upsurge of EV-D68 infections in same geographical area is supporting by study of Gilrane and colleagues which reported that the resurgence of EV-D68 infections was only recognized in 2014, 2016 and 2018 compared to 2015 and 2017 where only sporadic cases were detected [140] . The impact of geographical location in prevalence can be explained in USA context were several studies noticed a widespread of EV-D68 infections in 2014 and 2018 but only low-level circulation in 2016 in some states, such as Colorado, Missouri, and Ohio. In contrast, high prevalence of EV-D68 infections was reported in the Lower Hudson Valley and Philadelphia in 2016 [139, 140] .

The high prevalence observed in hospital outbreak in this study can be explained by nosocomial transmission of the virus. Indeed, evidence supporting the role of EV-D68 in respiratory infections in hospitalised patients has been provided in several countries as Spain [141] , in Italy [24], Japan [142] and USA [143] .

As in our study, it has been reported in several studies that the paediatric population is more vulnerable to EV-D68 infections [22, 33, 70] . EV-D68 infections has mostly been reported in children probably because of the lower amount of physical space in the airways than in adults but also the immaturity of their immune system [19, 78, 87, 106, 144] . Although children are at higher risk for severe respiratory symptoms than are adults [64,78, [144] [145] [146] [147] [148] , cases of respiratory disease associated with EV-D68 have been reported in both healthy adults and adults with under lying respiratory diseases or immunosuppression [149] . However, although constituted of four clades and five subclades, including clade A, clade B (subclades B1 to B3), clade C and clade D (subclades D1 to D2), recent studies reported that EV-D68 clade D1 is more likely to cause respiratory infections in adults than in children [26, 96, 115, 150] . Nonetheless, AFM occurs almost exclusively in children [151] . Indeed, these major co-circulating EV-D68 (AC) clades emerged in the world in the 2000s [6] and subsequently diversified, with a single monophyletic group (genotypes B1 and B3) with a common ancestor in 2009 associated until now at AFM [152] . In vitro studies of the neurotropism of these viruses compared to ancestral strains have given conflicting results as to whether neurotropism increased [153, 154] . The timing of increased transmission estimated in a recent study in the UK on the basis of serological data analysis roughly corresponds to the genetic emergence of clade B around 2007, and it could be hypothesized that increased transmissibility of the virus is a trait associated with this clade [155] . More efficient viral replication may improve transmission as well as the likelihood of the virus reaching the central nervous system, although changes in receptor use may also play a role [155] . Regarding immunity, studies that more closely investigated EV-D68 infections seroepidemiology in children noted a low population antibody prevalence around one year of age, with a gradual rise in the presence of EV-D68 neutralizing antibodies through childhood [115, 156] . A recent study shown also that natural EV-D68 infections of humans induces B cells encoding broad and potently neutralizing antibodies that can prevent or treat infection and disease in both the respiratory tract and the nervous system [157] . In addition, EV-D68 phylogenetic of pattern does not suggest continuous immune escape [158] and a broad range of cross-reactivity among clades of EVD68, both with binding and neutralization was also observed by Vogt et al. [157] .

High prevalence of EV-D68 infections in people with asthma was observed in this study. Indeed, it has been shown that EV-D68 infections peaks in 2014 and 2018 were related to an increase in summertime hospitalizations for asthma in USA, which agrees with a study conducted in Japan [145] . Some studies have shown a more severe clinical course among hospitalized children with EV-D68 infections who have pre-existing asthma [20, 159] , whereas others have not observed this difference [16, 160] .

In this study, from 5263 participants with AFM, an overall prevalence of EV-D68 current infections of 11.3% was obtained. However, although other pathogens like enterovirus A71 and West Nile virus have been recognized responsible to AFM, EV-D68 is associated for the majority of AFM cases. However, several evidences have been shown which support that the AFM was caused by EV-68. The first is the coincidence of outbreaks of EV-68 and the increase of AFM case in 2014, 2016 and 2018 [35, 37, 156] . In addition, EV-D68 was found predominantly in specimens from patients with AFM [52, 113, 151] . The second evidence has been highlighted by two independent studies on sera and CSF of AFM patients who have demonstrated a strong antibody enrichment associated with enteroviruses, including antibodies against a specific epitope of the EV-D68 in up to 73% of patients [161, 162] . In addition, multiple mouse models of EV-D68 have been developed that replicate key features of AFM [163] [164] [165] [166] [167] and Koch's postulates for causation were fulfilled in one mouse model [164] . Two others analyses have also concluded that the Bradford Hill criteria support a causative relationship between EV-D68 and AFM in humans [39, 168] . Moreover, these facts may explain the high prevalence of EV-D68 in AFM, which corroborates with the high prevalence of 22.5 and 27.8 observed in California from 2012 to 2015 [118] and in Canada in 2014 and 2018 [127] , respectively.

Past infections were investigated in this review in patients with acute flaccid myelitis and presumed healthy individuals and EV-D68 past infections prevalence of 66.3% was found with a range from 2.0 to 100.0%. As the result, anti-EV-D68 neutralizing antibodies levels have been gradually increasing worldwide with a geometric mean titer 40.50 in 2002 in the Finnish [1] and a highest antibody titer reached 676.08 in the Kansas City population from 2011 to 2013 [115] . In additions, after the 2014 EV-D68 infections outbreak in the United States, the geometric means of the titers of anti-EV-D68 neutralizing antibodies in human sera was up to 14, 562 [169] . Moreover, the presence of neutralizing antibodies is a widely accepted correlate of immunity and protection against severe disease associated with EV infection [170] . Thus, age-stratified serosurveys of neutralizing antibodies are a valuable method of understanding the prevalence of EV-D68 infections and evaluating the risk of an outbreak among the general population.

One of the main limitations of this study is the poverty or lack of data observed in resource limited settings. Furthermore, the role played by EV-D68 in the deaths reported in this review is unclear. Most of the published work included in this review retrospectively tested EV-D68 in nasopharyngeal swabs and therefore could likely underestimate the reported prevalences. The heterogeneity between diagnostic tools used in different included studies also constitutes a limit in the detection of EV-D68. Regarding the diagnostic, in this study we also considered all AFP as AFM. However, a consensus case definition applicable in all WHO regions will help differentiate between AFM and other neurological complications. Although there were some limitations, this is to the very best of our knowledge, the first review with meta-analysis summarizing data on the global prevalence of EV-D68 infections. This review also allowed us to map the articles published on the EV-D68 infections and to see the data gap observed in countries with limited resources. This article also highlighted the importance of AFM cases associated with EV-D68, nosocomial infections and the vulnerability of children with asthma.

In the absence of a vaccine, prevention is based on strict respect with universal hygiene rules, and in particular hand washing, to stop the chain of transmission within the family and the community. EV-D68 infections outbreak observed in hospital in this study demands effective implementation of vigorous prevention and control strategies to break nosocomial EV-D68 infections. For that personal protective equipment (PPE), like face masks, will help to prevent the spread EV-D68 infections. In addition, until more progress in treatment is achieved; we recommend that the children population should remain shielded during EV-D68 infection outbreaks. For a better understanding of the virus and the diseases caused, efficient and standardized laboratory diagnosis and characterization of circulating viral strains is the first step towards effective and continuous surveillance activities.

In conclusion, the high prevalence observed in these studies shows that EV-D68 should be considered a pathogen emerging. The large-scale outbreak of 2014, 2016 and 2018, sometimes associated with respiratory infections complicated by severe neurological damage, must encourage the implementation of continuous global surveillance. However, standardization of detection systems, types of samples and case definitions, especially for AFM, would be a real advance in understanding about the mechanisms for the sudden upsurge in incidence and its unusual and severe complex disease manifestations.

Supporting information S1 

Cellular tropism of human enterovirus D species serotypes EV-94, EV-70, and EV-68 in vitro: implications for pathogenesis

Virology, epidemiology, pathogenesis, and control of enterovirus 71

New respiratory enterovirus and recombinant rhinoviruses among circulating picornaviruses

The epidemiology of non-polio enteroviruses: recent advances and outstanding questions

Fluorescent cell counting as an assay method for respiratory syncytial virus

Worldwide emergence of multiple clades of enterovirus 68

Global emergence of enterovirus D68: a systematic review

Clusters of acute respiratory illness associated with human enterovirus 68-Asia, Europe, and United States

Enterovirus D68 infection in children with acute flaccid Myelitis

Outbreak of enterovirus D68 of the new B3 lineage in

Clinical characteristics of children infected with enterovirus D68 in an outpatient clinic and the association with bronchial asthma. Infectious Diseases

Acute flaccid paralysis following enterovirus D68 associated pneumonia

Severe respiratory illness associated with enterovirus D68-Missouri and Illinois, 2014. MMWR Morbidity and mortality weekly report

Emergence of enterovirus D68 in Denmark

Molecular and clinical comparison of enterovirus D68 outbreaks among hospitalized children

Enterovirus D68 Infection among Children with Medically Attended Acute Respiratory Illness

Enterovirus D68-associated community-acquired pneumonia in children

Surveillance summary of hospitalized pediatric enterovirus D68 cases in Canada

Acute flaccid myelitis among hospitalized children in Texas

Enterovirus D68-associated respiratory infection in southern Brazil

Enterovirus D68 in Critically Ill Children: A Comparison with Pandemic H1N1 Influenza. Pediatric Critical Care Medicine

Low-level circulation of enterovirus D68-associated acute respiratory infections

Epidemiological analysis of acute respiratory infections caused by enterovirus D68 Glade A, subclade A1 in the adult population

Ferré s F. Community acquired acute respiratory infections caused by enterovirus D68 (EV-D68)

Enterovirus 68 in pediatric patients hospitalized for acute airway diseases

Frequent detection of enterovirus D68 and rhinovirus type c in children with acute respiratory tract infections

Australian National Enterovirus Reference Laboratory annual report

Australian National Enterovirus Reference Laboratory annual report

Cluster of acute flaccid paralysis and cranial nerve dysfunction in children temporally associated with an enterovirus D68 outbreak in Colorado

Epidemiological and clinical characteristics of patients infected with enterovirus D68

Clinical Course of Enterovirus D68 in Hospitalized Children. The Pediatric infectious disease journal

Results of Nationwide Surveillance. Clinical Infectious Diseases

Detection of multiple viral sequences in the respiratory tract samples of suspected Middle East respiratory syndrome coronavirus patients in Jakarta

Seroepidemiology of enterovirus D68 infection in infants and children in Jiangsu

Prevalence and phylogenetic characterization of enterovirus D68 in pediatric patients with acute respiratory tract infection in Thailand

Longitudinal molecular microbial analysis of influenza-like illness

Acute flaccid myelitis of unknown etiology in California

EV-D68 infection in children with asthma exacerbation and pneumonia in Mexico City during 2014 autumn. Influenza and other Respiratory Viruses

Molecular Detection and Genomic Characterization of Enterovirus D68 among Children with Severe Acute Respiratory Infection in Beijing and Shanghai. Bing du xue bao = Chinese journal of virology

Human enterovirus D68 in clinical and sewage samples in Israel

Coxsackievirus A21, enterovirus 68, and acute respiratory tract infection, China. Emerging Infectious Diseases

Seroepidemiology of enterovirus D68 infection in China. Emerging microbes & infections

Genetic divergence of enterovirus D68 in China and the United States

Prevalence and molecular characterizations of enterovirus D68 among children with acute respiratory infection in China between

Seasonal alteration of isolated pathogens in children hospitalized with asthma exacerbation

Association of outcomes in acute flaccid myelitis with identification of enterovirus at presentation: a Canadian, nationwide, longitudinal study. The Lancet Child and Adolescent Health

Respiratory infections associated with enterovirus D68 from 2011 to 2015 in Beijing

Enterovirus D68-associated severe pneumonia, China

Board of Scientific Counselors. National overview of acute flaccid myelitis-United States

Enterovirus D68 molecular and cellular biology and pathogenesis

Enterovirus D68 Antivirals: Past, Present, and Future

Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis

Rise in acute flaccid myelitis cases reported in the US and Europe

Low Circulation of Subclade A1 Enterovirus D68 Strains in Senegal during

Molecular detection of enterovirus D68 among children with acute respiratory tract infection in Ghana

Severe paediatric conditions linked with EV-A71 and EV-D68, France

Continued biennial circulation of enterovirus D68 in Colorado

Association of enterovirus D68 with acute flaccid myelitis

Biennial upsurge and molecular epidemiology of enterovirus D68 infection

First Enterovirus D68 (EV-D68) cases detected in hospitalised patients in a tertiary care university hospital in Spain

Outbreak of Enterovirus D68 Among Children in Japan-Worldwide Circulation of Enterovirus D68 Clade B3

A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study

Enterovirus 68 infection in children with asthma attacks: virus-induced asthma in Japanese children

Phylogenetic characterization of enterovirus 68 strains in patients with respiratory syndromes in Italy

Coexistence of two clades of enterovirus D68 in pediatric Swedish patients in the summer and fall of 2014

Molecular evolution of enterovirus 68 detected in the Philippines

Lineages, sub-lineages and variants of enterovirus 68 in recent outbreaks

Enterovirus D68-associated respiratory and neurological illness in Spain

Vital Signs: Surveillance for Acute Flaccid Myelitis-United States

Nextstrain: real-time tracking of pathogen evolution

Understanding Enterovirus D68-Induced Neurologic Disease: A Basic Science Review

Contemporary Circulating Enterovirus D68 Strains Have Acquired the Capacity for Viral Entry and Replication in Human Neuronal Cells. mBio

Changes in transmission of Enterovirus D68 (EV-D68) in England inferred from seroprevalence data. medRxiv

Increase in enterovirus D68 infections in young children

Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease

Unifying the epidemiological and evolutionary dynamics of pathogens

Mejias reports personal fees from Abbvie and Novartis, grants from Gilead, Alios and Janssen. These grants and fees were not related to the research described in this manuscript. No other authors reported financial disclosures

Epidemiological and clinical characteristics of patients infected with enterovirus D68, France

Pan-viral serology implicates enteroviruses in acute flaccid myelitis

Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis

Neurotropism of Enterovirus D68 Isolates Is Independent of Sialic Acid and Is Not a

A mouse model of paralytic myelitis caused by enterovirus D68

A Mouse Model of Enterovirus D68 Infection for Assessment of the Efficacy of Inactivated Vaccine. Viruses

Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice

Causation of Acute Flaccid Paralysis by Myelitis and Myositis in Enterovirus-D68 Infected Mice Deficient in Interferon alphabeta/gamma Receptor Deficient Mice. Viruses

The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68)-what is the evidence for causation?

Neutralization of Enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products

The Picornaviruses

None.